Christopher A Young

US Patent:

7553855, Jun 30, 2009

Filed:

May 14, 2007

Appl. No.:

11/748073

Inventors:

Christopher R. Young - Waltham MA, US
Charles William Rowe - Medford MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/47

US Classification:

514312

Abstract:

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

US Patent:

8076357, Dec 13, 2011

Filed:

May 26, 2009

Appl. No.:

12/471950

Inventors:

Christopher R. Young - Waltham MA, US
Charles William Rowe - Medford MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/47

US Classification:

514312

Abstract:

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

US Patent:

8410274, Apr 2, 2013

Filed:

Jan 26, 2012

Appl. No.:

13/358778

Inventors:

Patricia Hurter - Harvard MA, US
William Rowe - Medford MA, US
Christopher Ryan Young - Waltham MA, US
Adriana Costache - Roslindale MA, US
Patrick R. Connelly - Harvard MA, US
Mariusz Krawiec - Marlborough MA, US
Yuchuan Gong - Waukegan IL, US
Yushi Feng - Zionsville IN, US
Martin Trudeau - Shannon, CA

Assignee:

Vertex Pharmaceuticals - Cambridge MA

International Classification:

C07D 215/38

US Classification:

546159, 546156, 514312

Abstract:

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

US Patent:

8457942, Jun 4, 2013

Filed:

Oct 20, 2010

Appl. No.:

12/908597

Inventors:

Gregory A. Harrison - Oviedo FL, US
Salaheddine Saidi - St. Petersburg FL, US
Russell (Russ) Chan - Sunnyvale CA, US
Ann N. McCauslin - Aldie VA, US
Howard S. Kern - Silver Spring MD, US
Jeffrey S. Coffin - Germantown MD, US
David C. Benjamin - Orlando FL, US
Lawrence G. Elliott - Orlando FL, US
Christopher A. Young - Quincy MA, US
Stephen D. Peckham - Brighton MA, US
Michael D. Stewart - Wyncote PA, US
Mark E. Barbustiak - Atco NJ, US

Assignee:

Lockheed Martin Corporation - Orlando FL

International Classification:

G06F 17/50
G06G 7/62

US Classification:

703 13

Abstract:

Systems and methods for parallel, discrete, simulations include functional capabilities to incorporate one or more human operators or actors into the simulation process. Such individuals can be presented situations where one or more decisions are necessary with respect to ongoing events. Entered decisions are incorporated into simulated events and activities being simulated. These in turn influence the behavior of those entities and also initiate the occurrence of other time-based processes. An architecture artifact or product can be automatically created or updated by recording how a sequence of events took place. The creation of sections of the DoDAF OV-6C Operational Event Trace architectural diagram, for the executable architecture model, can be automatically performed to dynamically provide event traces in response to a live exercise.

US Patent:

8552034, Oct 8, 2013

Filed:

Apr 7, 2011

Appl. No.:

13/081750

Inventors:

Marinus Jacobus Verwijs - Framingham MA, US
Ritu Rohit Kaushik - Watertown MA, US
Irina Nikolaevna Kadiyala - Newton MA, US
Christopher Young - Waltham MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/443
C07D 405/12

US Classification:

514338, 5462837

Abstract:

A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

US Patent:

20020130894, Sep 19, 2002

Filed:

Mar 15, 2001

Appl. No.:

09/809618

Inventors:

Christopher Young - Waltham MA, US
Michael Langlie - Belmont MA, US

International Classification:

G06F003/00

US Classification:

345/706000, 345/764000

Abstract:

A computer-implemented system includes generating a character and an object on a portion of a World Wide Web page, causing the character to interact with the object in response to a user input, and controlling movement of the character based on identities of the character and the object. An environment, such as a room, may also be generated for the character and the object. The environment houses the character and the object.

US Patent:

20070239418, Oct 11, 2007

Filed:

Mar 23, 2007

Appl. No.:

11/690349

Inventors:

Gregory Harrison - Oviedo FL, US
Salaheddine Saidi - Orlando FL, US
Russell Chan - Sunnyvale CA, US
Ann McCauslin - Aldie VA, US
Howard Kern - Silver Spring MD, US
Jeffrey Coffin - Germantown MD, US
David Benjamin - Orlando FL, US
Lawrence Elliott - Orlando FL, US
Christopher Young - Quincy MA, US
Stephen Peckham - Brighton MA, US
Michael Stewart - Wyncote PA, US
Mark Barbustiak - Atco NJ, US

International Classification:

G06F 17/50

US Classification:

703013000

Abstract:

Systems and methods for parallel, discrete, simulations include functional capabilities to incorporate one or more human operators or actors into the simulation process. Such individuals can be presented situations where one or more decisions are necessary with respect to ongoing events. Entered decisions are incorporated into simulated events and activities being simulated. These in turn influence the behavior of those entities and also initiate the occurrence of other time-based processes. An architecture artifact or product can be automatically created or updated by recording how a sequence of events took place. The creation of sections of the DoDAF OV-6C Operational Event Trace architectural diagram, for the executable architecture model, can be automatically performed to dynamically provide event traces in response to a live exercise.

US Patent:

20100074949, Mar 25, 2010

Filed:

Aug 13, 2009

Appl. No.:

12/583066

Inventors:

William Rowe - Medford MA, US
Patricia Hurter - Harvard MA, US
Christopher Young - Waltham MA, US
Kirk Dinehart - Holliston MA, US
Marinus Jacobus Verwijs - Framingham MA, US
Kirk Overhoff - Waltham MA, US
Peter D.J. Grootenhuis - San Diego CA, US
Martyn Botfield - Concord MA, US
Alfredo Grossi - Somerville MA, US

International Classification:

A61K 9/28
A61K 31/47
A61K 9/42
A61K 9/44
A61P 3/00
A61P 19/10

US Classification:

424467, 514312, 424474, 424476

Abstract:

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.